H.R. 5463 · 117th Congress · House

Drug Pricing Transparency and Accountability Act

Active· Referred to the Subcommittee on Health.
Introduced
Sep 30, 21
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Drug Pricing Transparency and Accountability Act

This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

Action Timeline

5
  1. OCT 01, 2021•Committee

    Referred to the Subcommittee on Health.

  2. SEP 30, 2021•IntroReferral

    Introduced in House

  3. SEP 30, 2021•IntroReferral

    Introduced in House

  4. SEP 30, 2021•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. SEP 30, 2021•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committees

3

Health Subcommittee

hsif14

Referred: Oct 1, 2021

Active

Ways and Means Committee

hswm00

Referred: Sep 30, 2021

Active

Energy and Commerce Committee

hsif00

Referred: Sep 30, 2021

Active